Rohingya crisis: UN has ‘no right to interfere’ says Myanmar army chief

Washington D.C., April 21: North Korea's leader, Kim Jong Un, is in grave danger following a surgery this month, according to a US intelligence official with direct knowledge.

Kim recently missed the celebration of his grandfather's birthday on April 15, which raised speculation about his well-being. He had been seen four days before that at a government meeting, according to intelligence reports cited by CNN.

The National Security Council and Office of the Director of National Intelligence have however declined to comment on the matter.

CNN has also reached out to the CIA and the State Department for comment and sought comment from the South Koreans.

Kim's absences from official state media often spark speculation and rumors about his health. North Korea has no free press and is often a black hole when it comes to the country's leadership. Analysts are heavily reliant on scanning state media dispatches and watching propaganda videos for any semblance of a clue.

Kim last appeared in North Korean state media on April 11. April 15 -- North Korea's most important holiday, the anniversary of the birth of the country's founding father, Kim Il Sung -- came and went without any official mention of Kim Jong Un's movements.

Experts are unsure of what to make of Kim's absence from any festivities celebrating his grandfather. When North Korean leaders have not shown up to these important celebrations in the past, it has portended major developments. But it has also turned out to be nothing.

"There have been a number of recent rumours about Kim's health (smoking, heart, and brain). If Kim is hospitalized, it would explain why he wasn't present on the important April 15th celebrations," said Bruce Klingner, a senior research fellow at the Heritage Foundation and former CIA deputy division chief for North Korea. "But, over the years, there have been a number of false health rumors about Kim Jong-un or his father. We'll have to wait and see."

Kim Jong Il's absence from a parade celebrating North Korea's 60th anniversary in 2008 was followed by rumblings that he was in poor health. It was later revealed he had a stroke, after which his health continued to decline until his death in 2011.

Kim Jong Un disappeared from the public eye for more than a month in 2014, which also prompted speculation about his health. He returned sporting a cane, and days later South Korean intelligence said that he had a cyst removed from his ankle.

Wuhan, Feb 16: The death toll from China's coronavirus epidemic has climbed to 1,665 after 142 more people died, mostly in the worst-hit Hubei Province, and the confirmed cases jumped to 68,500, officials said on Sunday, as top WHO experts scramble to assist Beijing contain the virus spread.

China's National Health Commission confirmed 2,009 new cases across the country.

Hubei and its provincial capital Wuhan, where the virus first emerged in December, reported 1,843 of the new cases. The latest report brought the total confirmed cases in Hubei to 56,249 cases.

Of the new deaths, 139 were in Hubei, two in Sichuan, and one in Hunan, the state-run Xinhua news agency reported.

The number of new cases, however, appears to have started dropping and a top Chinese health official has said efforts to control the outbreak have reached the “most crucial stage".

The report said 9,419 infected patients had been discharged from hospital after recovery so far.

The coronavirus has posed a severe threat to the medical staff as more than 1,700 Chinese health officials have been infected by the virus while treating the patients and six of them have died.

Experts from the World Health Organisation are expected in Beijing on Sunday to join Chinese health authorities in containing the virus, which has spread to several other countries forcing them to temporarily stop tourist arrivals from China.

The health commission said a joint mission with WHO experts will pay field visits to China's three provincial-level regions to learn the effectiveness of the epidemic control measures.

One task of the mission will be to come up with standard medicine to cure the disease, according to the health commission.

Several antiviral drugs are under clinical trials and Chinese researchers have narrowed down their focus to a few existing drugs, including Chloroquine Phosphate, Favipiravir and Remdesivir, said Zhang Xinmin, director of the China National Centre for Biotechnology Development.

Experts have asked people to frequently wash hands and face, and wear masks.

Authorities have begun quarantining large quantity of bank notes and coins in the affected areas and sanitising them with UV light before releasing them back into circulation to stop the virus from spreading.

Canadian researchers are developing a DNA vaccine for SARS-CoV-2, the coronavirus that causes COVID-19 and has currently infected nearly 5,00,000 people worldwide and crippled the global economy.

Entos Pharmaceuticals, a health-care biotechnology company headed by a University of Alberta researchers, develop new therapeutic compounds using the company's proprietary drug-delivery platform and has begun manufacturing vaccine candidates against the novel coronavirus.

"Given the urgency of the situation, we can have a lead candidate vaccine within two months. Once we have that it's a race to get it into clinical trials," said John Lewis, CEO of Entos and a Professor at the University of Alberta in Canada.

Lewis said in comparison to a traditional vaccine, DNA-based vaccines hold several advantages.

Nucleic acids are introduced directly into the patient's own cells, causing them to make pieces of the virus--tricking the immune system into mounting a response without the full virus actually being present, the researcher said.

According to the company, the approach is recognised as being easier to move into large-scale manufacturing, offers improved vaccine stability and works without needing an infectious agent.

In the current absence of a vaccine for COVID-19, several companies around the world are mounting efforts to begin similar work.

The first clinical trial using a DNA-based vaccine developed by Moderna Inc.in the US on March 13.

Their approach allows for antibodies to be made in the human trial volunteers against a specific protein on the surface of the coronavirus that lets the virus enter human cells.

The hope is that the antibodies will stop the interaction.

Though this approach is designed to be effective against COVID-19 specifically, Lewis said Entos is taking a different tack.

The company plans to use plasmid DNA to amplify the production of key coronavirus surface and structural proteins with each injection, with an eye to the bigger picture.

"Many of the structural proteins in the virus are pretty well conserved across all the coronaviruses, including SARS and MERS," said Lewis.

"We're hoping that if we express more of the structural proteins that are common to most coronaviruses, we can inhibit the current COVID-19, and also potentially protect against all coronaviruses both past and future," Lewis added.

To move the project forward quickly, the company is seeking financial support from both provincial and federal levels of government.

"We have the opportunity to save a lot of lives, and I think it's really upon us and governments to find solutions for that," Lewis said.